Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia

Diagnostic Microbiology and Infectious Disease

Volumn 67, Issue 3, 2010, Pages 228-233

  Neuner, Elizabeth A ^a   Casabar, Ed ^b   Reichley, Richard ^c   McKinnon, Peggy S ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c BJC Healthcare ^*  (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Bacteremia; MRSA; Vancomycin

Indexed keywords

METICILLIN; PANTON VALENTINE LEUKOCIDIN; VANCOMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 77953674561     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.02.026     Document Type: Article

References (25)

1. Bone R.C., Balk R.A., Cerrar F.B., Dellinger R.P., Fein A.M., Knaus W.A., Schein R.M., Sibbald W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
2. Boye K.B.M., Andersen S., Moller J.A., Westh H. A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types I-V. Clinical Microbiology and Infection 2007, 13(7):725-727.
3. Davis S.L., Rybak M.J., Amjad M., Kaatz G.W., Mckinnon P.S. Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2006, 27:1025-1031.
4. Fowler V.G., Sakoulas G., McIntyre L.M., Meka V.G., Arbeit R.D., Cabell C.H., Stryjewski M.E., Eliopoulos G.M., Reller L.B., Corey G.R., Jones T., Lucindo N., Yeaman M.R., Bayer A.S. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004, 190:1140-1149.
5. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., Levine D.P., Chambers H.F., Tally F.P., Vigliani G.A., Cabell C.H., Link A.S., DeMeyer I., Filler S.G., Zervos M., Cook P., Parsonnet J., Bernstein J.M., Savor-Price C., Forrest G.N., Gatkenheuer G., Gareca M., Rehm S.J., Reinhardt-Brodt H., Tice A., Cosgrove S.E. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355(7):653-665.
6. Friedman N.D., Kaye K.S., Stout J.E., McGarry S.A., Trivette S.L., Briggs J.P., Lamm W., Clark C., MacFarquhar J., Walton A.L., Reller L.B., Sexton D.J. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137:791-797.
7. Ganga R., Riederer K., Sharma K., Fakih M.G., Johnson L.B., Shemes S., Khatib R. Role of SCCmec type in outcome of Staphylococcus aureus bacteremia in a single medical center. J Clin Microbiol 2009, 47:590-595.
8. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections. Am J Infect Control 1988, 16(3):128-140.
9. Hawkins C., Huang J., Jin N., Noskin G.A., Zembower T.R., Bolon M. Persistent Staphylococcus aureus bacteremia. Arch Intern Med 2007, 167:1861-1867.
10. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch of Intern Med 2006, 166:2138-2144.
11. Jeffres M.N., Isakow W., Doherty J.A., McKinnon P.S., Ritchie D.J., Micek S.T., Kollef M.H. Predictors of mortality for methicillin-resistant Staphylococcus aureus heath-care-associated pneumonia. Chest 2006, 130:947-955.
12. Johnson L.B., Almoujahed M.O., Ilg K., Maolood L., Khatib R. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003, 35:782-789.
13. Khatib R., Riederer K., Saeed S., Johnson L.B., Fakih M., Sharma M., Tabriz M.S., Khosrovaneh A. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with source and outcome of infection. Clin Infect Dis 2005, 41:594-598.
14. Khatib R., Johnson L.B., Fakih M.G., Riederer K., Khosrovaneh A., Tabriz M.S., Sharma M., Saeed S. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006, 38:7-14.
15. Lina G., Piemont Y., Godail-Gamot F., Bes M., Peter M.O., Gauduchon V., Vandenesch F., Etienne J. Involvement of Panton-Valentine leukocidin producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128-1132.
16. Maclayton D.O., Suda K.J., Coval K.A., York C.B., Garey K.W. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/ml and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006, 28(8):1208-1216.
17. Mohr J.F., Murray B.E. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007, 44:1536-1542.
18. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., Schentag J.J., Forrest A., Robert C., Moellering J. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004, 38:1700-1705.
19. Moise-Broder P.A., Forrest A., Birmingham M.C., Shentag J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43(13):925-942.
20. Naimi T.S., LeDell K.H., Como-Sabetti K., Borchardt S.M., Boxrud D.J., Etienne J., Johnson S.K., Vandenesch F., Fridkin S., O Boyle C., Danila R.N., Lynfield R. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003, 290(22):2976-2984.
21. Prakash V., Lewis J.S., Jorgensen J.H. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008, 52:4528.
22. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Robert C., Moellering J., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42(6):2398-2402.
23. Siegman-Igra Y., Reich P., Orni-Wasserlauf R., Schwartz D., Giladi M. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteremia. Scand J Infect Dis 2005, 37:572-578.
24. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., Alamo D., Ortega M., Lopez J., Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
25. Stevens D.L. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006, 42(Suppl 1):S51-S57.